KalVista Pharmaceuticals, Inc.
KALVHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, KalVista Pharmaceuticals, Inc. focuses on Biotechnology services and products. KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. The company carries a $1.43B market cap, placing it firmly in the small-cap category. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE).
Market Cap
$1.43B
Beta
-0.12
P/E (TTM)
—
P/E (Fwd)
22.45
EPS (TTM)
$-3.94
EPS (Fwd)
$1.20
ROE
—
ROA
—
Cash
$285.0M
Total Debt
$284.3M
Free CF
—
52W Change
108.0%
Annual Financials
Cash vs Debt
With $285.0M in cash and $284.3M in debt, KALV maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating.
KALV's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence KalVista Pharmaceuticals, Inc.'s trajectory.